Skip to main content

Table 1 IWQOL-Lite Summary (Age ≥ 18 Years)

From: Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency

 

Patient 1a

Patient 2a

Patient 3a

Patient 4b

Patient 5b

Patient 6b

Patient 7b

Mean (SD)

IWQOL-Lite total score at baseline

50

43

70

74

77

52

56

60.3 (13.3)

Change in IWQOL-Lite total score at Week 52

44

31

17

23

21

9

24.2 (12.1)

Relevant improvement cutoffs for IWQOL-Lite total score [26]c

12.0

12.0

12.0

8.3

8.2

12.0

12.0

Percent change in IWQOL-Lite total score at Week 52

88.0

72.1

24.3

31.1

27.3

16.1

43.1 (29.4)

Change in domain scores at Week 52

        

 PF

34

25

4

18

28

0

18.2 (13.6)

 SL

50

69

0

39.7 (35.6)

 W

63

38

19

62

19

7

34.7 (23.7)

 PD

40

30

0

10

25

20

20.83 (14.3)

 SE

47

39

18

29

7

14

25.7 (15.4)

Body weight, percent change

 − 34.8

 − 25.8

 − 27.7

 − 21.0

 − 15.6

 − 2.3

 − 21.2 (11.3)

Most hunger, percent change

 − 14.3

 − 5.8

 − 72.2

 − 64.3

 − 66.7

 − 37.5

 − 43.5 (28.7)

  1. IWQOL-Lite, Impact of Weight on Quality of Life-Lite; LEPR, leptin receptor; PD, public distress; PF, physical functioning; POMC, proopiomelanocortin; SD, standard deviation; SE, self-esteem; SL, sexual life; W, work
  2. aPatient enrolled in POMC trial
  3. bPatient enrolled in LEPR trial
  4. cImprovement and deterioration cutoff scores are dependent on baseline IWQOL-Lite total scores